Bicycle Therapeutics plc (BCYC) Misses Q2 EPS by 21c

Bicycle Therapeutics plc (NASDAQ: BCYC) reported Q2 EPS of ($1.41), $0.21 worse than the analyst estimate of ($1.20). Revenue for the quarter came in at $11.4 million versus the consensus estimate of $5.78 million.

For earnings history and earnings-related data on Bicycle Therapeutics plc (BCYC) click here.

You May Also Be Interested In

• JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
• YETI Holdings, Inc. (YETI) Tops Q2 EPS by 12c
• Park Dental Partners, Inc. (PARK) Tops Q2 EPS by 28c